Mark Reardon on Muck Rack

Mark Reardon

Verified
St. Louis
As seen in: KMOX-AM (St. Louis, MO), Mark Reardon Show, MDPI, U.S. Army, Royal Society of Chemistry, Audacy.com, KCBS-AM (San Francisco, CA), KDKA-AM (Pittsburgh, PA), KFTK-FM (St. Louis, MO), KJKK-FM (Dallas, TX), KMBZ-FM (Kansas City, MO), KRLD-AM (Dallas, TX) and
@971FMTALK Talk Show Host/Movie Critic,@DietCoke addict, music fanatic. @mizzou alum. I wear headphones for a living. @criticschoice/@sagaftra/@stlfilmcritics
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark

Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Why Hospitals Struggle with the Value-Based Journey and How Leading Organizations Have Found a Path Forward

|
By Mark Reardon Verified, Brian Buesing
| Fierce Healthcare Verified
Many hospitals continue to struggle with turning healthcare data into actionable, cost-effective care strategies. The roadblocks typically fall into two categories: 1. Overreliance on internal or proprietary data, which may omit vital diagnostics from external labs or miss broader population health insights 2.
Open in Who Shared Issue with article?

Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy

|
By Mark Reardon Verified, Translational Oncogenomics, Daniel E. Spratt, Alex Hakansson
| International Journal of Radiation Oncology*Biology*Physics Verified
Keywords prostate cancer biochemical recurrence hypoxia androgen deprivation therapy Introduction Prostate cancer (PCa) is diagnosed in 1.4 million men globally each year and causes 375,000 deaths, making PCa the second-most common cancer and fifth-most common cause of cancer death in men [1]. Patients are stratified by clinical parameters such as blood prostate-specific antigen (PSA) levels, tumour T-stage and histopathological Gleason grade group into low, intermediate, and high-risk PCa [2].
Open in Who Shared Issue with article?

Investigating the impact of the interstitial fluid flow and hypoxia interface on cancer biology using a spheroid-on-chip perfusion system

|
By Emily Pyne, Mark Reardon Verified, Martin Christensen, Scott Taylor
| Royal Society of Chemistry Verified
Investigating the impact of the interstitial fluid flow and hypoxia interface on cancer biology using a spheroid-on-chip perfusion system Solid tumours are complex and heterogeneous systems, which exist in a dynamic biophysical microenvironment.
Open in Who Shared Issue with article?
See all 1,857 licensed articles (1,858 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified